Chairman has gone22 Apr 2015 14:30
LEXINGTON, Mass., April 21, 2015 (GLOBE NEWSWIRE) -- Xenetic Biosciences, Inc. (OTCBB:XBIO), a biopharmaceutical company focused on developing next-generation biologic drugs and novel oncology therapeutics, announces the resignation of Chairman Mark Leuchtenberger.
CEO of Xenetic Scott Maguire said, "We want to thank Mark for his seasoned board guidance over the last year, helping a previously European company navigate the complex US regulatory environment. Unfortunately the demands of his new CEO position at Chiasma make it impossible to maintain his chairman's role for Xenetic. I want to thank Mark again for his service the past year and I wish him luck in his new venture."
The company plans to keep the chair role vacant until a suitable candidate can be found.